CRISPR Therapeutics AG (NASDAQ:CRSP) finished Friday with a subtraction of -$0.42 to close at $49.65, a downside of -0.84 percent. An average of 1,414,780 shares of common stock have been traded in the last five days. There was a fall of -$1.31 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 1,082,110 shares traded, while the 50-day average volume stands at 1,132,042.
CRSP stock has decreased by -15.85% in the last month. The company shares reached their 1-month lowest point of $48.25 on 08/07/23. With the stock rallying to its 52-week high on 05/23/23, shares of the company touched a low of $38.94 and a high of $83.79 in 52 weeks. It has reached a new high 14 times so far this year and achieved 22.14% or $9.00 in price. In spite of this, the price is down -40.74% from the 52-week high.
Insider Transactions
CRSP stock investors should be aware that CRISPR Therapeutics AG (CRSP) stock had its last reported insider trading activity 74 days ago on May 30. In this transaction, the insider spent $1,621,894. Chief Executive Officer, Kulkarni Samarth, disposed of 25,000 shares at a price of $50.67 on Apr 25. The insider now owns more than $1,266,638 worth of shares. Prior to that, Chief Executive Officer Kulkarni Samarth went on to Sale 25,000 shares at $44.46 each on Mar 29. An amount of $1,111,504 was transacted.
Valuation Metrics
CRISPR Therapeutics AG (CRSP) stock’s beta is 1.61. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 39.37, the price-to-book (PB) ratio at 2.11.
Financial Health
The quick ratio of CRISPR Therapeutics AG for the three months ended June 29 was 13.00, and the current ratio was 13.00, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $674.36 million compared to revenue of $1.2 million.
Earnings Surprise
For the three-month period that ended June 29, CRISPR Therapeutics AG had $1.32 billion in cash. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$77.74 million in the quarter, while revenues were shrunk -139.04%. The analyst consensus anticipated CRISPR Therapeutics AG’s latest quarter earnings to come in at -$2.12 per share, but it turned out to be -$0.98, a 53.80% surprise. For the quarter, EBITDA amounted to -$90.26 million. Shareholders own equity worth $79.41 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at CRISPR Therapeutics AG (CRSP) price momentum. RSI 9-day as of the close on 11 August was 36.01%, suggesting the stock is Neutral, with historical volatility in this time frame at 66.35%.
As of today, CRSP’s price is $50.41 -2.57% or -$1.31 from its 5-day moving average. CRSP is currently trading -12.76% lower than its 20-day SMA and +11.67% higher than its 100-day SMA. However, the stock’s current price level is -22.47% below the SMA50 and -1.49% below the SMA200.
The stochastic %K and %D were 19.83% and 25.48%, respectively, and the average true range (ATR) was 2.45. With the 14-day stochastic at 14.07% and the average true range at 2.43, the RSI (14) stands at 37.56%. The stock has reached -1.31 on the 9-day MACD Oscillator while the 14-day reading was at -3.07.
Analyst Ratings
William Blair launched coverage on CRISPR Therapeutics AG (NASDAQ: CRSP) in its analyst report released on May 30, 2023. The firm assigned the stock an Outperform rating.
